IRVINE, Calif., April 28 /PRNewswire-FirstCall/ -- Endologix, Inc., developer of minimally invasive treatments for aortic disorders, announced today the publication of consolidated results from its prospective, multicenter clinical trials of the Company’s Powerlink® stent graft for the endovascular repair of abdominal aortic aneurysms (AAA) using an anatomical fixation technique. The trial results demonstrate no aneurysm ruptures, no conversions to open repair, no device migrations, no stent fractures, no graft fatigue, no junctional endoleaks, no transgraft endoleaks, and 100% freedom from aneurysm-related mortality for up to five years post-implant. In addition, core lab evaluations found a low rate of limb occlusion (0.6% of limbs), with significantly reduced or stable aneurysm sacs in 95% and 93% of patients at one year and five years, respectively.
